Scarica l'app Stockscreener
25.50
2.75%
-0.72
Dopo l'orario di chiusura:
25.50
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACAD Giù?
Forum
Previsione
Acadia Pharmaceuticals Inc Borsa (ACAD) Ultime notizie
An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors? - Yahoo Finance
Acadia rises as EU backs Rett syndrome therapy - MSN
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
ACADIA Pharmaceuticals (ACAD) Names A New Chief People Officer, Is It Still Below Fair Value? - Yahoo Finance
Why Acadia Pharmaceuticals stock is soaring today - MSN
ACADIA Pharmaceuticals (ACAD) Stock Looks Undervalued After A 21% Run - Sahm
Is ACADIA Pharmaceuticals (ACAD) Still Undervalued After The Daybue Win? - Yahoo Finance
Is ACADIA Pharmaceuticals (ACAD) Undervalued On Rett Progress And Its Leadership Change? - simplywall.st
How CHMP’s Positive Rett Syndrome Ruling on DAYBU Could Impact ACADIA Pharmaceuticals (ACAD) Investors - Yahoo Finance
H.C. Wainwright Keeps Their Buy Rating on ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Carl Segerstrom Appointed Chief People Officer at Acadia Pharmaceuticals - hrtoday.in
Should EMA’s Positive Rett Syndrome Opinion for DAYBU Reshape ACADIA Pharmaceuticals’ (ACAD) Investment Narrative? - Sahm
RBC Capital Adjusts Price Target on ACADIA Pharmaceuticals to $36 From $29, Maintains Outperform Rating - Moomoo
RBC Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $36 - Moomoo
Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer - BioSpace
ACADIA Pharmaceuticals Inc. (ACAD) Latest Stock News & Headlines - Yahoo Finance
Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief Talent Officer - GuruFocus
Acadia taps 25-year HR veteran for chief people officer role - Stock Titan
ACADAcadia Pharmaceuticals Inc Forecast, Target Price - Finviz
Understanding the Setup: (ACAD) and Scalable Risk - Stock Traders Daily
Price to sales forward of ACADIA Pharmaceuticals Inc. – NASDAQ:ACAD - TradingView
Price to book forward of ACADIA Pharmaceuticals Inc. – NASDAQ:ACAD - TradingView
Acadia Pharma EVP Schneyer sells $60k in stock - Investing.com
Price to earnings forward of ACADIA Pharmaceuticals Inc. – BIVA:ACAD - TradingView
Price to book forward of ACADIA Pharmaceuticals Inc. – LSX:603035 - TradingView
Canaccord reiterates Acadia Pharmaceuticals stock rating on Q1 results - Investing.com
ACAD stock eyes best day in over a year as CHMP recommends approval for rare nerve disorder drug in Europe - MSN
ACAD INVESTORS WHO LOST MONEY: HAGENS BERMAN, National Trial Attorneys, Alerts Acadia Pharmaceuticals (ACAD) Investors to Securities Class Action, Advises Investors with Losses to Contact Its Attorneys Now - TMX Newsfile
ACADIA Pharmaceuticals (ACAD) In Focus As Europe Backs Daybue And Undervalued View Holds - simplywall.st
ACAD Maintains Buy Rating -- Price Target Raised to $30.00 by B of A Securities - GuruFocus
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $30 to $37 - Moomoo
H.C. Wainwright reiterates Acadia Pharmaceuticals stock rating on EU progress - Investing.com Australia
ACADIA Pharmaceuticals Price Target Raised to $35.00/Share From $32.00 by Citigroup - Moomoo
Insider Sell: James Kihara Sells Shares of ACADIA Pharmaceuticals Inc (ACAD) - GuruFocus
Acadia Pharmaceuticals principal accounting officer sells $297,912 - Investing.com UK
Acadia Pharmaceuticals principal accounting officer sells $297,912 By Investing.com - Investing.com Nigeria
Form 4 ACADIA Pharmaceuticals Inc For: 29 June By Investing.com - Investing.com Nigeria
ACADIA PHARMACEUTICALS (ACAD) officer sells 11,421 shares under 10b5-1 plan - Stock Titan
ACAD stock up as CHMP backs Daybu for EU approval in Rett syndrome - MSN
ACAD Maintained by Canaccord Genuity -- Price Target Raised to $36.00 - GuruFocus
ACAD Maintained by Citigroup -- Price Target Raised to $35 - GuruFocus
ACAD Stock Up as CHMP Backs Daybu for EU Approval in Rett Syndrome - The Globe and Mail
EMA reverses its stance on Acadia’s Rett syndrome therapy Daybu - BioWorld News
Acadia Pharmaceuticals: Steady Commercial Progress, Remlifanserin Data In Focus - Seeking Alpha
Acadia Pharmaceuticals (ACAD) Receives Positive CHMP Opinion for DAYBU Approval - GuruFocus
Acadia Pharmaceuticals: Steady Commercial Progress, Remlifanserin Data In Focus (NASDAQ:ACAD) - Seeking Alpha
Strength Seen in Acadia (ACAD): Can Its 6.8% Jump Turn into More Strength? - Yahoo Finance
Deutsche Bank Raises Price Target on ACADIA Pharmaceuticals to $37 From $32, Keeps Buy Rating - marketscreener.com
Canaccord raises Acadia Pharmaceuticals price target on EU approval By Investing.com - Investing.com Canada
Acadia Pharmaceuticals (ACAD) Gets 90-Day Catalyst Watch from Ci - GuruFocus
DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP - BioSpace
Citi Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $35 - Moomoo
5.60%
0.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):